Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Alligator Bioscience Presents at the 20th Annual Rodman & Renshaw Global Investment Conference


LUND, Sweden, Aug. 30, 2018 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.

CEO Per Norlén will provide an overview of the Company's business during the live presentation, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event: Company presentation at the 20th Annual Rodman & Renshaw Global Investment Conference

Date: September 6, 2018

Time: 3:25-3:50 pm EDT (9:25-9:50 pm CEST)

Location: Library (2nd floor); the St. Regis New York Hotel in New York City

The presentation will be webcast live. To access the webcast, please use the direct link http://wsw.com/webcast/rrshq28/atorx/ or visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation.

For further information, please contact:
Cecilia Hofvander
Director Investor Relations & Communications
Phone +46-46-286-44-95
E-mail: [email protected] 

The information was submitted for publication, through the agency of the contact person set out above, at 2:00 p.m. CEST on August 30, 2018.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527).

ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/alligator-bioscience/r/alligator-bioscience-presents-at-the-20th-annual-rodman---renshaw-global-investment-conference,c2604652

The following files are available for download:

http://mb.cision.com/Main/12681/2604652/900104.pdf

Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: